Akers Biosciences, Inc. Independent Sales Representative Agreements - PIFA
July 18 2018 - 6:00AM
RNS Non-Regulatory
TIDMAKR
Akers Biosciences, Inc.
18 July 2018
July 18, 2018
Akers Biosciences, Inc.
Akers Biosciences Signs a Further Independent Sales
Representative Organization for Heparin PF4 Rapid Test Covering
Additional 12 States
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a developer of rapid health information
technologies, announces another agreement with a major Independent
Sales Representative (ISR) organization, adding sales and marketing
coverage for the Company's rapid test for heparin-induced
thrombocytopenia (HIT) across an additional 12 states.
The agreement with Appleton Medical Services, based in St.
Louis, Missouri, will place Akers Bio's flagship HIT test into the
hands of a further 14 speciality medical product sales
representatives, focused on implementing solutions into the
clinical pathway.
Appleton Medical Services will target clinical end-users of, and
those able to prescribe, HIT tests, including surgeons and surgical
teams. Their teams will provide sales and marketing exposure for
PIFA Heparin/PF4 Rapid Assay products in Indiana, Kentucky,
Minnesota, Illinois, Wisconsin, Mississippi, Louisiana, Missouri,
Kansas, Iowa, Nebraska and Arkansas; as well as providing coverage
in certain areas of Texas, Wyoming and Colorado which are not
currently represented by existing ISR partners with coverage in
those states.
Since the start of 2018, Akers Bio has developed sales and
marketing coverage through ISRs in 39 of the 50 United States,
covering more than 75 per cent of the country's total
population.
John J. Gormally, Chief Executive Officer of Akers Bio,
commented: "A key goal for Akers Bio has been to establish broad
Independent Sales Representative coverage for our primary
commercialized test, leveraging the specialized skills and relevant
relationships of our chosen partners in their respective regions.
This is central to the strategy of raising awareness of the
benefits of our rapid heparin platelet factor 4 antibody test and
to influencing the clinical pathway for the diagnosis of HIT.
As a result of the tremendous efforts of our sales and marketing
team, we are now represented by 55 sales people from 9
organizations covering 39 states which are home to over
three-quarters of the US population. We fully expect to further
expand this footprint as we focus on driving profitable growth for
our core products."
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Note Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements reflect the Company's expectations about its future
operating results, performance and opportunities that involve
substantial risks and uncertainties. Such statements may include,
without limitation, statements with respect to the Company's plans,
compliance with the requirements of various regulatory agencies,
objectives, projections, expectations and intentions and other
statements identified by words such as "projects," "may," "will,"
"could," "would," "should," "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "potential" or similar
expressions, as they relate to the Company, its subsidiaries, or
its management. These statements are based upon the current beliefs
and expectations of the Company's management and are subject to
significant risks and uncertainties, including those detailed in
the Company's filings with the Securities and Exchange Commission.
Actual results, performance, prospects, and opportunities to may
differ materially from those set forth in, or implied by, the
forward-looking statements. These forward-looking statements
involve certain risks and uncertainties that are subject to change
based on various factors (many of which are beyond the Company's
control). The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7390 0234
Email: akers@vigocomms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADMGMNGRMGRZM
(END) Dow Jones Newswires
July 18, 2018 07:00 ET (11:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2023 to May 2024